Effect of the Mushroom Extract Andosan on Symptoms and Inflammatory Parameters in Patients With Rheumatoid Arthritis (RA)
The clinical trial investigating AndoSan, a mushroom extract, for the treatment of rheumatoid arthritis (RA) addresses a significant unmet need in a market characterized by limited efficacy of existing therapies and high patient demand for alternative treatments. With RA affecting approximately 0.4-0.5% of the population in Norway and higher incidence rates in women, the potential for AndoSan to provide a novel therapeutic option could position it favorably in the competitive landscape. The trial's completion suggests readiness for further development, possibly leading to expanded clinical trials or partnerships with larger pharmaceutical entities. The results could enhance the marketability of AndoSan, particularly if they demonstrate significant improvements in symptom management and quality of life for RA patients.
Indication: Rheumatoid Arthritis
Modality: RNA therapy
Target: Immunomodulatory effects through modulation of cytokine levels and inflammatory parameters.
Sponsor: Egil Johnson
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Immunomodulatory effects through modulation of cytokine levels and inflammatory parameters.
View original source fields
Condition raw: Rheumatoid Arthritis
Condition normalized: Rheumatoid Arthritis
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Immunomodulatory effects through modulation of cytokine levels and inflammatory parameters.
Target normalized: Immunomodulatory effects through modulation of cytokine levels and inflammatory parameters.